New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
作者信息
Mason Robert G
出版信息
J R Soc Promot Health. 2003 Jun;123(2):79-80. doi: 10.1177/146642400312300209.
PMID:12852189
Abstract
摘要
相似文献
1
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
J R Soc Promot Health. 2003 Jun;123(2):79-80. doi: 10.1177/146642400312300209.
2
Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
Curr Urol Rep. 2004 Dec;5(6):451-9. doi: 10.1007/s11934-004-0070-2.
3
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Curr Opin Urol. 2003 Sep;13(5):405-10. doi: 10.1097/00042307-200309000-00008.
4
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Circulation. 2004 Nov 9;110(19):3149-55. doi: 10.1161/01.CIR.0000146906.42375.D3.
5
Tadalafil and vardenafil.
Nat Rev Drug Discov. 2004 Apr;3(4):295-6. doi: 10.1038/nrd1362.
6
Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
Expert Opin Pharmacother. 2005 Jan;6(1):1-2. doi: 10.1517/14656566.6.1.1.
7
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
World J Urol. 2005 Dec;23(6):374-84. doi: 10.1007/s00345-005-0022-6. Epub 2005 Nov 5.
8
Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Am J Geriatr Cardiol. 2004 Nov-Dec;13(6):332-5. doi: 10.1111/j.1076-7460.2004.02725.x.
9
Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
J Sex Med. 2004 Nov;1(3):322-36. doi: 10.1111/j.1743-6109.04047.x.
10
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Int J Impot Res. 2002 Dec;14(6):466-71. doi: 10.1038/sj.ijir.3900910.
Zotero 插件